Navigation Links
Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference
Date:12/7/2009

SAN DIEGO, Dec. 7 /PRNewswire/ -- Ambit Biosciences Corporation announced today that preliminary results from a clinical trial of its lead product candidate, AC220, in acute myeloid leukemia (AML) were presented at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans. AC220 is a novel, orally available, small molecule that was expressly optimized as a FMS-like tyrosine kinase-3 (FLT3) inhibitor for the treatment of AML.

The open-label, dose-escalation study, "AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase Inhibitor, in a First-in-Human Phase I AML Study," was designed to evaluate the safety, tolerability, and pharmacokinetic profile of AC220 in AML patients with predominantly relapsed or refractory disease. AC220 was generally well-tolerated in AML patients, and importantly, there was no treatment-related mortality observed in this study. Clinical response and median survival were assessed as secondary endpoints and analyzed for the overall study population, in addition to patient subsets based on the presence or absence of the FLT3 genotype for the internal tandem duplication (ITD) mutation (FLT3 ITD+ and FLT3 ITD-, respectively). Following treatment with AC220, responses were observed in both FLT3 ITD+ and FLT3 ITD- patients, and responders in each group had at least a doubling in median survival versus non-responders.

"AML represents a challenging hematological malignancy to treat. A significant portion of AML patients have activating FLT3 mutations, and these patients have a particularly poor prognosis and are often refractory to current treatment options," said Jorge Cortes MD, Internist and Professor, Deputy Chair, Department of Leukemia, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, and primary investigator for the Phase I Study. "These encouraging results with AC220 warrant further studies of this promising
'/>"/>

SOURCE Ambit Biosciences Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting
2. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
8. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
9. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
10. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
11. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Hovione today announced that its API ... passed a pre-approval inspection by the US Food and Drug ... FDA Consumer Safety Officer, Ms. Britanny Terhar , lasted ... July and concluded on the 25 th . The inspection ... guidelines of Good Manufacturing Practices (GMP) and no Form 483 ...
(Date:7/31/2014)... the list of stocks featured in the Analyst Blog. Every ... and events impacting stocks and the financial markets. Stocks recently ... Free Report ), Gilead (Nasdaq: GILD - Free Report ... AbbVie (NYSE: ABBV - Free Report ) and Celgene ... Zacks is promoting its ,Buy, stock recommendations. Get #1Stock ...
(Date:7/31/2014)... , July 31, 2014 TB Alliance, a ... and affordable treatments for tuberculosis (TB), announced the appointment ... Market Access. Ms. Robertson joins the organization from Novartis ... in Sub-Saharan Africa and Eastern Europe ... TB Alliance,s efforts to ensure beneficial new TB treatments ...
Breaking Medicine Technology:Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6TB Alliance Names Elana Robertson Senior Vice President, Market Access 2TB Alliance Names Elana Robertson Senior Vice President, Market Access 3
(Date:7/31/2014)... 31, 2014 On October 10, ... Illinois, the Mesothelioma Applied Research Foundation, in collaboration ... a one-day regional mesothelioma conference geared ... of topics related to mesothelioma and presented by ... covered topics will include imaging, genetics, first-line therapies, ...
(Date:7/31/2014)... Hoping to attract new customers who are looking for ... is ready to ship out free samples of product. A ... this offer fast and easy: http://www.nutrigold.com/Free-Samples , According ... "We know that every time customers purchase one of our ... their own health or the health of a loved one ...
(Date:7/31/2014)... NV (PRWEB) July 31, 2014 0-6 Pack ... Tyler Bramlett and physical therapist expert Dr. James Vegher. ... waistlines, fix back pain, relieve digestive issues, tone core muscles, ... a specific sequence of core exercises used to re-train the ... , After a quick 0-6 Pack Abs review, ...
(Date:7/31/2014)... In today’s world, a good night’s sleep ... and sleep apnea (a medical problem where the airway collapses ... partners of the rest they need to face their daily ... and 20 million people in the United States alone have ... treated; and of those treated, many cannot tolerate their prescribed ...
(Date:7/31/2014)... Hook Your Ex, a system created by Steve ... emotionally hungry for their partner, to the point of starvation, that ... trick has been taught to hundreds of men and women across ... Your Ex review , Shane Michaels agrees this simple trick is ... breakup a second chance at getting back together with their ex. ...
Breaking Medicine News(10 mins):Health News:October Events: Regional Conference on Mesothelioma in Chicago 2Health News:October Events: Regional Conference on Mesothelioma in Chicago 3Health News:NutriGold Launches Product Samples Page for its Supplements 2Health News:NutriGold Launches Product Samples Page for its Supplements 3Health News:Zero To Six Pack Abs System Review Exposes Tyler Bramlett And Dr. James Veghers’ New Ab Training Program 2Health News:Zero To Six Pack Abs System Review Exposes Tyler Bramlett And Dr. James Veghers’ New Ab Training Program 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Hook Your Ex Review by Shane Michaels Exposes Steve Pratt And His New Method For Getting Back With The Ex 2
... ... ... ... ...
... ... the leading provider of professional Accounts Receivable based funding and credit management solutions in ... the industries projected to generate the highest number of new jobs over the next ... ...
... ... company prepares to launch a range of new products. , ... London, UK (PRWEB) February 19, 2010 -- Freedom Healthnet ( ... launch a range of new products., , ,Freedom Healthnet is already a market leader in ...
... ... region’s standing within football’s international arena, it is with great pleasure that international direct ... in support of Asian football. , ... (PRWEB) February 19, 2010 -- As the Official Direct Selling Supporter ...
... magnetic resonance imaging (MRI) may help physicians differentiate between ... wrist enabling more targeted therapies unique to each condition, ... the American Journal of Roentgenology . Contrast-enhanced MRI ... bodily structures. Rheumatoid arthritis ...
... , ... ... ... ...
Cached Medicine News:Health News:MDS Announces Substantial Issuer Bid 2Health News:MDS Announces Substantial Issuer Bid 3Health News:MDS Announces Substantial Issuer Bid 4Health News:MDS Announces Substantial Issuer Bid 5Health News:MDS Announces Substantial Issuer Bid 6Health News:United Capital continues to lead in funding 2Health News:Freedom Healthnet Affirms Affordable Private Health Insurance Benefits 2Health News:QuestNet and AFC: Raising the Bar of Asian Football 2Health News:QuestNet and AFC: Raising the Bar of Asian Football 3Health News:Contrast-enhanced MRI could play a key role in differentiating between common types of arthritis 2Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 2Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 3Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 4Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 5Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 6Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 7Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 8Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 9Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 10Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 11Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 12Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 13Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 14Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 15Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 16Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 17Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 18Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 19Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 20Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 21Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 22Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 23Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 24Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 25Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 26
... flexible lighting products. The first is available ... sizes 5", 10", and 15" (refers to ... These lights are for use in procedures ... second group of flexible lights is our ...
These units, though small, still offer sufficient output to ensure current is fully adjustable from 0 to 70 mA. Instruction manual, ball electrodes, battery and leads with alligator clips are include...
These units, though small, still offer sufficient output to ensure current is fully adjustable from 0 to 70 mA. Instruction manual, ball electrodes, battery and leads with alligator clips are include...
... Modes of Operation: , Standby: A standby switch ... , Double Burst : 2 60-ms bursts of 50 ... , Twitch: 1 s (1 pulse/s); 2 Hz (2 ... 100 Hz (100 pulses/s) , Train-Of-Four: 4 pulses/2 s; ...
Medicine Products: